Travere Therapeutics Inc. (TVTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Travere Therapeutics Inc. (TVTX) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How TVTX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $490.7M | 97.9% | -12.8% | -$25.5M | $15.7M | -20.5% |
| FY 2024 | $233.2M | 96.7% | -138.9% | -$321.5M | -$248.0M | -45% |
| FY 2023 | $145.2M | 44% | -267.2% | -$111.4M | -$286.6M | -19.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring TVTX)
- ✓Live walkthrough of TVTX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
TVTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +110.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TVTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TVTX. Explore sector supply chains on /butterfly.
TVTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Travere Therapeutics Inc. (TVTX)?
In FY 2025 (10-K), TVTX converted $490.7M of revenue into a 97.9% gross margin, 0% operating margin, and $15.7M in free cash flow (3.2% FCF margin).